The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISAL 2023 | The importance of evaluating heterogeneity in AML and how this may impact MRD assessment
Jacqueline Cloos, PhD, Amsterdam UMC, Amsterdam, The Netherlands, briefly discusses the importance of investigating clonal evolution in acute myeloid leukemia (AML) to better understand how this may impact accurate measurable residual disease (MRD) assessment. This interview took place at the 18th International Symposium on Acute Leukemias (ISAL XVIII), held in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Disclosure (institute) received research funding from Takeda, DC-one, Genentech, Janssen, Novartis, Merus and royalties from Navigate and BD Biosciences.
